Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor, Inc. (not Avalo Therapeutics, Inc.) on July 10, 2019. The registrant is a Delaware corporation with its principal executive offices in Rockville, Maryland. The company is classified as an Emerging Growth Company and its common stock trades on the Nasdaq Capital Market under the symbol CERC.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the release of an updated investor presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure requirements regarding the posting of new investor materials.
Guidance, Outlook, and Management Commentary
On July 10, 2019, Cerecor, Inc. posted an updated Investor Presentation to its website (www.cerecor.com). The content of this presentation is attached as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the company name is Cerecor, Inc., as the input metadata incorrectly referenced Avalo Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Investor Presentation) for actual financial data, guidance, and strategic updates, as this 8-K only announces its existence.
- Note that the presentation materials are not legally "filed" with the SEC and carry different liability standards than the 8-K itself.
- Confirm the company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.